Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Kidney Cancers
share announcement

Kidney Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (15 April 2021) | Viewed by 14293

Special Issue Editors

Prof. Dr. Michele Milella

E-Mail Website
Guest Editor
Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy
Interests: precision oncology; molecularly targeted therapy; lung and thoracic cancers; hepato-bilio-pancreatic cancers; kidney cancer; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals
Prof. Alessandro Antonelli

E-Mail Website
Guest Editor
Section of Urology, University of Verona-School of Medicine, AOUI Verona, Italy
Interests: renal cell carcinoma; prostate cancer; urothelial carcinoma; testicular cancer; laparoscopy; robotics
Prof. Dr. Matteo Brunelli

E-Mail Website
Guest Editor
Department of Diagnostic and Public Health, Section of Pathology, University of Verona, 37134 Verona, Italy
Interests: tumours arising from the urogenital tracts (renal carcinoma, prostate adenocarcinoma, bladder cancer)

Special Issue Information

Dear Colleagues, 

Kidney cancers represent the 6th most frequently diagnosed malignancy in men and the 10th in women and cause more than 140,000 deaths yearly worldwide, ranking as the 13th most common cause of cancer death.

Over the past 20 years, our knowledge of renal cell carcinoma (RCC) biology and our ability to detect it, classify it correctly, and treat it effectively has grown exponentially: New morphological/molecular entities have been identified; surgical indications and techniques have evolved, allowing for a tailored, patient-centered, approach; and targeted and immunological drugs and combinations have transformed advanced RCC into a chronic disease, which is entirely managed based on its underlying biology.

The ambitious aim of this Special Issue is to provide an update on the state-of-the-art and future perspectives in the biology and classification, prognostic/predictive evaluation, and multidisciplinary treatment of RCC, ushering this fascinating disease into a new era of precision RCC oncology.

Prof. Dr. Michele Milella
Prof. Alessandro Antonelli
Prof. Matteo Brunelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kidney cancer
  • biology
  • histological classification
  • prognostic/predictive biomarkers
  • curative surgery
  • palliative surgery
  • advanced disease
  • targeted therapy
  • immunotherapy
  • combination therapy

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 6357 KiB  
Article
Prognostic Factors Affecting Survival after Pulmonary Resection of Metastatic Renal Cell Carcinoma: A Multicenter Experience
by Elisa Meacci, Dania Nachira, Edoardo Zanfrini, Jessica Evangelista, Elizabeth Katherine Anna Triumbari, Maria Teresa Congedo, Leonardo Petracca Ciavarella, Marco Chiappetta, Maria Letizia Vita, Giovanni Schinzari, Ernesto Rossi, Giampaolo Tortora, Marco Lucchi, Marcello Ambrogi, Fabrizia Calabrò, Francesco Petrella, Lorenzo Spaggiari, Marco Mammana, Andrea Lloret Madrid, Federico Rea, Diomira Tabacco and Stefano Margaritoraadd Show full author list remove Hide full author list
Cancers 2021, 13(13), 3258; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133258 - 29 Jun 2021
Cited by 5 | Viewed by 1626
Abstract
In this paper we aimed to address the role of pulmonary metastasectomy (PM) in patients affected by Lung Metastases (LM) from Renal Cell Carcinoma (RCC) and to analyse prognostic factors affecting overall survival (OS), disease-free interval (DFI) between primary RCC and first LM, [...] Read more.
In this paper we aimed to address the role of pulmonary metastasectomy (PM) in patients affected by Lung Metastases (LM) from Renal Cell Carcinoma (RCC) and to analyse prognostic factors affecting overall survival (OS), disease-free interval (DFI) between primary RCC and first LM, and disease-free survival (DFS) after PM and before lung recurrence. Medical records of 210 patients who underwent PM from RCC in 4 Italian Thoracic Centres, from January 2000 to September 2019, were collected and analysed. All patients underwent RCC resection before lung surgery. The main RCC histology was clear cells (188, 89.5%). The 5- and 10-year OS from the first lung operation were 60% and 34%, respectively. LM synchronous with RCC (p = 0.01) and (Karnofsky Performance Status Scale) KPSS < 80% (p < 0.001) negatively influenced OS. Five- and 10-year DFI were 54% and 28%, respectively. The main factors negatively influencing DFI were: male gender (p = 0.039), KPSS < 80% (p = 0.009) and lactate dehydrogenase > 1.5 times 140 U/L (p = 0.001). Five- and 10-year disease-free survival were 54% and 28%, respectively; multiple LM (p = 0.036), KPSS < 80% (p = 0.001) and histology of RCC other than clear cells negatively influenced disease-free survival. Conclusions: patients with KPSS > 80%, single metachronous LM with a long DFI from RCC diagnosis, and clear cell histology, benefit from pulmonary metastasectomy. Full article
(This article belongs to the Special Issue Kidney Cancers)
►▼ Show Figures

Figure 1

23 pages, 3022 KiB  
Article
Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma
by Chiara Gargiuli, Pierangela Sepe, Anna Tessari, Tyler Sheetz, Maurizio Colecchia, Filippo Guglielmo Maria de Braud, Giuseppe Procopio, Marialuisa Sensi, Elena Verzoni and Matteo Dugo
Cancers 2021, 13(12), 2903; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13122903 - 10 Jun 2021
Cited by 8 | Viewed by 2387
Abstract
Collecting duct carcinoma (CDC) is a rare and highly aggressive kidney cancer subtype with poor prognosis and no standard treatments. To date, only a few studies have examined the transcriptomic portrait of CDC. Through integration of multiple datasets, we compared CDC to normal [...] Read more.
Collecting duct carcinoma (CDC) is a rare and highly aggressive kidney cancer subtype with poor prognosis and no standard treatments. To date, only a few studies have examined the transcriptomic portrait of CDC. Through integration of multiple datasets, we compared CDC to normal tissue, upper-tract urothelial carcinomas, and other renal cancers, including clear cell, papillary, and chromophobe histologies. Association between CDC gene expression signatures and in vitro drug sensitivity data was evaluated using the Cancer Therapeutic Response Portal, Genomics of Drug Sensitivity in Cancer datasets, and connectivity map. We identified a CDC-specific gene signature that predicted in vitro sensitivity to different targeted agents and was associated to worse outcome in clear cell renal cell carcinoma. We showed that CDC are transcriptionally related to the principal cells of the collecting ducts providing evidence that this tumor originates from this normal kidney cell type. Finally, we proved that CDC is a molecularly heterogeneous disease composed of at least two subtypes distinguished by cell signaling, metabolic and immune-related alterations. Our findings elucidate the molecular features of CDC providing novel biological and clinical insights. The identification of distinct CDC subtypes and their transcriptomic traits provides the rationale for patient stratification and alternative therapeutic approaches. Full article
(This article belongs to the Special Issue Kidney Cancers)
►▼ Show Figures

Figure 1

11 pages, 1504 KiB  
Article
Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center
by Giovanni Mauri, Francesco Alessandro Mistretta, Guido Bonomo, Nicola Camisassi, Andrea Conti, Paolo Della Vigna, Matteo Ferro, Stefano Luzzago, Daniele Maiettini, Gennaro Musi, Nicolò Piacentini, Gianluca Maria Varano, Ottavio de Cobelli and Franco Orsi
Cancers 2020, 12(5), 1183; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12051183 - 07 May 2020
Cited by 16 | Viewed by 1999
Abstract
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Sometimes, multiple ablations are needed. The aim of the present study was to evaluate the long-term results in patients with renal [...] Read more.
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Sometimes, multiple ablations are needed. The aim of the present study was to evaluate the long-term results in patients with renal mass treated with radiofrequency ablation (RFA) with both US and CT, with a focus on the multiple ablations rate. 149 patients (median age 67 years) underwent RFA from January 2008 to June 2015. Median tumor diameter was 25 mm (IQR 17–32 mm). Median follow-up was 54 months (IQR 44–68). 27 (18.1%) patients received multiple successful ablations, due to incomplete ablation (10 patients), local tumor progression (8 patients), distant tumor progression (4 patients) or multiple tumor foci (5 patients), with a primary and secondary technical efficacy of 100%. Complications occurred in 13 (8.7%) patients (6 grade A, 5 grade C, 2 grade D). 24 patients died during follow-up, all for causes unrelated to renal cancer. In conclusion, thermal ablations with the guidance of US and CT are safe and effective in the treatment of renal tumors in the long-term period, with a low rate of patients requiring multiple treatments over the course of their disease. Full article
(This article belongs to the Special Issue Kidney Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

30 pages, 1432 KiB  
Review
Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs
by Gonçalo Outeiro-Pinho, Daniela Barros-Silva, Margareta P. Correia, Rui Henrique and Carmen Jerónimo
Cancers 2020, 12(8), 2214; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12082214 - 07 Aug 2020
Cited by 10 | Viewed by 2528
Abstract
Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for [...] Read more.
Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more efficient patient management. Nonetheless, currently available tools provide limited information and novel strategies are needed. Over the years, a putative role of non-coding RNAs (ncRNAs) as disease biomarkers has gained relevance and is now one of the most prolific fields in biological sciences. Herein, we extensively sought the most significant reports on ncRNAs as potential RCTs’ diagnostic, prognostic, predictive, and monitoring biomarkers. We could conclude that ncRNAs, either alone or in combination with currently used clinical and pathological parameters, might represent key elements to improve patient management, potentiating the implementation of precision medicine. Nevertheless, most ncRNA biomarkers require large-scale validation studies, prior to clinical implementation. Full article
(This article belongs to the Special Issue Kidney Cancers)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

15 pages, 1812 KiB  
Systematic Review
Radiomics in Renal Cell Carcinoma—A Systematic Review and Meta-Analysis
by Julia Mühlbauer, Luisa Egen, Karl-Friedrich Kowalewski, Maurizio Grilli, Margarete T. Walach, Niklas Westhoff, Philipp Nuhn, Fabian C. Laqua, Bettina Baessler and Maximilian C. Kriegmair
Cancers 2021, 13(6), 1348; https://doi.org/10.3390/cancers13061348 - 17 Mar 2021
Cited by 40 | Viewed by 3443
Abstract
Radiomics may increase the diagnostic accuracy of medical imaging for localized and metastatic RCC (mRCC). A systematic review and meta-analysis was performed. Doing so, we comprehensively searched literature databases until May 2020. Studies investigating the diagnostic value of radiomics in differentiation of localized [...] Read more.
Radiomics may increase the diagnostic accuracy of medical imaging for localized and metastatic RCC (mRCC). A systematic review and meta-analysis was performed. Doing so, we comprehensively searched literature databases until May 2020. Studies investigating the diagnostic value of radiomics in differentiation of localized renal tumors and assessment of treatment response to ST in mRCC were included and assessed with respect to their quality using the radiomics quality score (RQS). A total of 113 out of 1098 identified studies met the criteria and were included in qualitative synthesis. Median RQS of all studies was 13.9% (5.0 points, IQR 0.25–7.0 points), and RQS increased over time. Thirty studies were included into the quantitative synthesis: For distinguishing angiomyolipoma, oncocytoma or unspecified benign tumors from RCC, the random effects model showed a log odds ratio (OR) of 2.89 (95%-CI 2.40–3.39, p < 0.001), 3.08 (95%-CI 2.09–4.06, p < 0.001) and 3.57 (95%-CI 2.69–4.45, p < 0.001), respectively. For the general discrimination of benign tumors from RCC log OR was 3.17 (95%-CI 2.73–3.62, p < 0.001). Inhomogeneity of the available studies assessing treatment response in mRCC prevented any meaningful meta-analysis. The application of radiomics seems promising for discrimination of renal tumor dignity. Shared data and open science may assist in improving reproducibility of future studies. Full article
(This article belongs to the Special Issue Kidney Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop